The (Patho)physiology of Fibrinogen γ′

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 4, 2016, Pages 344-355

  Macrae, Fraser L ^a   Domingues, Marco M ^a   Casini, Alessandro ^a   Ariëns, Robert A S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

arterial; clot structure; fibrinogen; FXIII; thrombin; thrombosis; venous

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; FIBRIN; FIBRINOGEN; FIBRINOGEN GAMMA; FIBRINOPEPTIDE; GLYCOPROTEIN; HISTIDINE; PROTEIN C; RECOMBINANT PROTEIN; THROMBIN; UNCLASSIFIED DRUG; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN FRAGMENT Y;

ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; FIBRIN CLOT; FIBRINOLYSIS; GENETICS; HAPLOTYPE; HEMOSTASIS; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PLEIOTROPY; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; VEIN THROMBOSIS; WOUND HEALING; ANIMAL; METABOLISM; PROTEIN MULTIMERIZATION;

ANIMALS; BLOOD COAGULATION; FACTOR XIII; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PROTEIN MULTIMERIZATION; THROMBIN; THROMBOSIS;

EID: 84971333695     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0036-1572353     Document Type: Article

References (105)

1. Kant J. A., Fornace A. J. Jr, Saxe D., Simon M. I., McBride O. W., Crabtree G. R. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A: 1985; 82 8 2344 2348
2. Mosesson M. W., Finlayson J. S., Umfleet R. A. Human fibrinogen heterogeneities. 3. Identification of chain variants. J Biol Chem: 1972; 247 16 5223 5227
3. Francis C. W., Marder V. J., Martin S. E. Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem: 1980; 255 12 5599 5604
4. Fornace A. J. Jr, Cummings D. E., Comeau C. M., Kant J. A., Crabtree G. R. Structure of the human gamma-fibrinogen gene. Alternate mRNA splicing near the 3′ end of the gene produces gamma A and gamma B forms of gamma-fibrinogen. J Biol Chem: 1984; 259 20 12826 12830
5. Peerschke E. I., Francis C. W., Marder V. J. Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood: 1986; 67 2 385 390
6. Chung D. W., Chan W. Y., Davie E. W. Characterization of a complementary deoxyribonucleic acid coding for the gamma chain of human fibrinogen. Biochemistry: 1983; 22 13 3250 3256
7. Chung D. W., Davie E. W. gamma and gamma' chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry: 1984; 23 18 4232 4236
8. Wolfenstein-Todel C., Mosesson M. W. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma'). Proc Natl Acad Sci U S A: 1980; 77 9 5069 5073
9. Wolfenstein-Todel C., Mosesson M. W. Carboxy-terminal amino acid sequence of a human fibrinogen gamma-chain variant (gamma'). Biochemistry: 1981; 20 21 6146 6149
10. Uitte de Willige S., de Visser M. C., Houwing-Duistermaat J. J., Rosendaal F. R., Vos H. L., Bertina R. M. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood: 2005; 106 13 4176 4183
11. Nowak-Göttl U., Weiler H., Hernandez I., et al. Fibrinogen alpha and gamma genes and factor V Leiden in children with thromboembolism: results from 2 family-based association studies. Blood: 2009; 114 9 1947 1953
12. Cheung E. Y., Uitte de Willige S., Vos H. L., et al. Fibrinogen gamma' in ischemic stroke: a case-control study. Stroke: 2008; 39 3 1033 1035
13. Mosesson M. W., Hernandez I., Raife T. J., et al. Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost: 2007; 5 1 62 69
14. Uitte de Willige S., Rietveld I. M., De Visser M. C., Vos H. L., Bertina R. M. Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. J Thromb Haemost: 2007; 5 6 1243 1249
15. Beyer K., Dandekar T., Keller W. RNA ligands selected by cleavage stimulation factor contain distinct sequence motifs that function as downstream elements in 3′-end processing of pre-mRNA. J Biol Chem: 1997; 272 42 26769 26779
16. Mannila M. N., Lovely R. S., Kazmierczak S. C., et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost: 2007; 5 4 766 773
17. Lovely R. S., Moaddel M., Farrell D. H. Fibrinogen gamma' chain binds thrombin exosite II. J Thromb Haemost: 2003; 1 1 124 131
18. Sabo T. M., Farrell D. H., Maurer M. C. Conformational analysis of gamma' peptide (410-427) interactions with thrombin anion binding exosite II. Biochemistry: 2006; 45 24 7434 7445
19. Pineda A. O., Chen Z. W., Marino F., Mathews F. S., Mosesson M. W., Di Cera E. Crystal structure of thrombin in complex with fibrinogen gamma' peptide. Biophys Chem: 2007; 125 2-3 556 559
20. Pospisil C. H., Stafford A. R., Fredenburgh J. C., Weitz J. I. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem: 2003; 278 24 21584 21591
21. de Bosch N. B., Mosesson M. W., Ruiz-Sáez A., Echenagucia M., Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost: 2002; 88 2 253 258
22. Fredenburgh J. C., Stafford A. R., Leslie B. A., Weitz J. I. Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. J Biol Chem: 2008; 283 5 2470 2477
23. Cooper A. V., Standeven K. F., Ariëns R. A. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood: 2003; 102 2 535 540
24. Moaddel M., Falls L. A., Farrell D. H. The role of gamma A/gamma ' fibrinogen in plasma factor XIII activation. J Biol Chem: 2000; 275 45 35656
25. Kremers R. M., Wagenvoord R. J., Hemker H. C. The effect of fibrin(ogen) on thrombin generation and decay. Thromb Haemost: 2014; 112 3 486 494
26. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci: 2001; 936 291 311
27. Lorand L., Maldonado N., Fradera J., Atencio A. C., Robertson B., Urayama T. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol: 1972; 23 1 17 27
28. Allan P., Uitte de Willige S., Abou-Saleh R. H., Connell S. D., Ariëns R. A. Evidence that fibrinogen γ' directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost: 2012; 10 6 1072 1080
29. Gaffney P. J., Whitaker A. N. Fibrin crosslinks and lysis rates. Thromb Res: 1979; 14 1 85 94
30. Siebenlist K. R., Mosesson M. W. Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem: 1994; 269 45 28414 28419
31. Greenberg C. S., Shuman M. A. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem: 1982; 257 11 6096 6101
32. Mosesson M. W., Finlayson J. S. Biochemical and chromatographic studies of certain activities associated with human fibrinogen preparations. J Clin Invest: 1963; 42 747 755
33. Siebenlist K. R., Meh D. A., Mosesson M. W. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry: 1996; 35 32 10448 10453
34. Moaddel M., Farrell D. H., Daugherty M. A., Fried M. G. Interactions of human fibrinogens with factor XIII: roles of calcium and the gamma' peptide. Biochemistry: 2000; 39 22 6698 6705
35. Siebenlist K. R., Meh D. A., Mosesson M. W. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost: 2001; 86 5 1221 1228
36. Siebenlist K. R., Mosesson M. W., Hernandez I., et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains. Blood: 2005; 106 8 2730 2736
37. Gersh K. C., Lord S. T. An investigation of factor XIII binding to recombinant gamma'/gamma' and gamma/gamma' fibrinogen [abstract]. Blood: 2006; 108 11 485a
38. Smith K. A., Adamson P. J., Pease R. J., et al. Interactions between factor XIII and the alphaC region of fibrinogen. Blood: 2011; 117 12 3460 3468
39. Lovely R. S., Boshkov L. K., Marzec U. M., Hanson S. R., Farrell D. H. Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol: 2007; 139 3 494 503
40. Omarova F., Uitte De Willige S., Ariëns R. A., Rosing J., Bertina R. M., Castoldi E. Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen γ'. J Thromb Haemost: 2013; 11 9 1669 1678
41. Segers K., Dahlbäck B., Bock P. E., Tans G., Rosing J., Nicolaes G. A. The role of thrombin exosites I and II in the activation of human coagulation factor V. J Biol Chem: 2007; 282 47 33915 33924
42. Omarova F., Uitte de Willige S., Simioni P., et al. Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasma. Blood: 2014; 124 9 1531 1538
43. Vu T. T., Stafford A. R., Leslie B. A., Kim P. Y., Fredenburgh J. C., Weitz J. I. Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. J Biol Chem: 2011; 286 35 30314 30323
44. Poon I. K., Patel K. K., Davis D. S., Parish C. R., Hulett M. D. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood: 2011; 117 7 2093 2101
45. Leung L. L. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest: 1986; 77 4 1305 1311
46. Laurens N., Koolwijk P., de Maat M. PM. Fibrin structure and wound healing. J Thromb Haemost: 2006; 4 5 932 939
47. Cheung E. YL, Weijers E. M., Tuk B., et al. Specific effects of fibrinogen and the γA and γ'-chain fibrinogen variants on angiogenesis and wound healing. Tissue Eng Part A: 2015; 21 1-2 106 114
48. Hawiger J., Timmons S., Kloczewiak M., Strong D. D., Doolittle R. F. gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. Proc Natl Acad Sci U S A: 1982; 79 6 2068 2071
49. Kloczewiak M., Timmons S., Hawiger J. Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain. Biochem Biophys Res Commun: 1982; 107 1 181 187
50. Kloczewiak M., Timmons S., Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res: 1983; 29 2 249 255
51. Kloczewiak M., Timmons S., Lukas T. J., Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry: 1984; 23 8 1767 1774
52. Harfenist E. J., Packham M. A., Mustard J. F. Effects of variant gamma chains and sialic acid content of fibrinogen upon its interactions with ADP-stimulated human and rabbit platelets. Blood: 1984; 64 6 1163 1168
53. Hettasch J. M., Bolyard M. G., Lord S. T. The residues AGDV of recombinant gamma chains of human fibrinogen must be carboxy-terminal to support human platelet aggregation. Thromb Haemost: 1992; 68 6 701 706
54. Farrell D. H., Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem: 1994; 269 1 226 231
55. Lancellotti S., Rutella S., De Filippis V., Pozzi N., Rocca B., De Cristofaro R. Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors. J Biol Chem: 2008; 283 44 30193 30204
56. Lovely R. S., Rein C. M., White T. C., et al. gammaA/gamma' fibrinogen inhibits thrombin-induced platelet aggregation. Thromb Haemost: 2008; 100 5 837 846
57. Nagy B. Jr, Simon Z., Bagoly Z., Muszbek L., Kappelmayer J. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost: 2009; 102 1 83 89
58. Cox A. D., Devine D. V. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood: 1994; 83 4 1006 1016
59. Kieffer N., Guichard J., Farcet J. P., Vainchenker W., Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem: 1987; 164 1 189 195
60. Francis C. W., Nachman R. L., Marder V. J. Plasma and platelet fibrinogen differ in gamma chain content. Thromb Haemost: 1984; 51 1 84 88
61. Mosesson M. W., Homandberg G. A., Amrani D. L. Human platelet fibrinogen gamma chain structure. Blood: 1984; 63 5 990 995
62. Uitte de Willige S., Standeven K. F., Philippou H., Ariëns R. A. The pleiotropic role of the fibrinogen gamma' chain in hemostasis. Blood: 2009; 114 19 3994 4001
63. Undas A., Ariëns R. A. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol: 2011; 31 12 e88 e99
64. Riedelová-Reicheltová Z., Kotlín R., Suttnar J., et al. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function. Thromb Haemost: 2014; 111 1 79 87
65. Park R., Doh H. J., An S. S., Choi J. R., Chung K. H., Song K. S. A novel fibrinogen variant (fibrinogen Seoul II; AalphaGln328Pro) characterized by impaired fibrin alpha-chain cross-linking. Blood: 2006; 108 6 1919 1924
66. Collet J. P., Soria J., Mirshahi M., et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood: 1993; 82 8 2462 2469
67. Fatah K., Hamsten A., Blombäck B., Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost: 1992; 68 2 130 135
68. Fatah K., Silveira A., Tornvall P., Karpe F., Blombäck M., Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost: 1996; 76 4 535 540
69. Undas A., Podolec P., Zawilska K., et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke: 2009; 40 4 1499 1501
70. Undas A., Zawilska K., Ciesla-Dul M., et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood: 2009; 114 19 4272 4278
71. Lovely R. S., Falls L. A., Al-Mondhiry H. A., et al. Association of gammaA/gamma' fibrinogen levels and coronary artery disease. Thromb Haemost: 2002; 88 1 26 31
72. Kim P. Y., Vu T. T., Leslie B. A., Stafford A. R., Fredenburgh J. C., Weitz J. I. Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin. J Biol Chem: 2014; 289 40 27494 27503
73. Falls L. A., Farrell D. H. Resistance of gammaA/gamma' fibrin clots to fibrinolysis. J Biol Chem: 1997; 272 22 14251 14256
74. Pieters M., Kotze R. C., Jerling J. C., Kruger A., Ariëns R. A. Evidence that fibrinogen γ' regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans. Blood: 2013; 121 16 3254 3260
75. Collet J. P., Nagaswami C., Farrell D. H., Montalescot G., Weisel J. W. Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol: 2004; 24 2 382 386
76. Gersh K. C., Nagaswami C., Weisel J. W., Lord S. T. The presence of gamma' chain impairs fibrin polymerization. Thromb Res: 2009; 124 3 356 363
77. Domingues M. M., Macrae F. L., Duval C., et al. Thrombin and fibrinogen γ' impact clot structure by marked effects on intrafibrillar structure and protofibril packing. Blood: 2015
78. Drouet L., Paolucci F., Pasqualini N., et al. Plasma gamma'/gamma fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Blood Coagul Fibrinolysis: 1999; 10 01 S35 S39
79. Farrell D. H. γ' Fibrinogen as a novel marker of thrombotic disease. Clin Chem Lab Med: 2012; 50 11 1903 1909
80. van den Herik E. G., Cheung E. Y., de Lau L. M., et al. Fibrinogen γ' levels in patients with intracerebral hemorrhage. Thromb Res: 2012; 129 6 807 809
81. Lovely R. S., Kazmierczak S. C., Massaro J. M., D'Agostino R. B. Sr, O'Donnell C. J., Farrell D. H. Gamma' fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem: 2010; 56 5 781 788
82. Pieters M., Boshuizen H., de Lange Z., et al. Relationship of coagulation and fibrinolytic variables with arterial structure and function in Africans. Thromb Res: 2014; 134 1 78 83
83. Lovely R., Hossain J., Ramsey J. P., et al. Obesity-related increased γ' fibrinogen concentration in children and its reduction by a physical activity-based lifestyle intervention: a randomized controlled study. J Pediatr: 2013; 163 2 333 338
84. Appiah D., Schreiner P. J., MacLehose R. F., Folsom A. R. Association of Plasma γ' Fibrinogen With Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol: 2015; 35 12 2700 2706
85. Cheung E. Y., Vos H. L., Kruip M. J., den Hertog H. M., Jukema J. W., de Maat M. P. Elevated fibrinogen gamma' ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood: 2009; 114 20 4603 4604, author reply 4604-4605
86. van den Herik E. G., Cheung E. Y., de Lau L. M., et al. γ'/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. Thromb Haemost: 2011; 105 3 430 434
87. Farrell D. H. Primetime for γ'. Blood: 2014; 124 9 1389 1390
88. Mosesson M. W., Cooley B. C., Hernandez I., Diorio J. P., Weiler H. Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding gamma' chain sequence. J Thromb Haemost: 2009; 7 1 102 110
89. Walton B. L., Getz T. M., Bergmeier W., Lin F. C., Uitte de Willige S., Wolberg A. S. The fibrinogen γA/γ' isoform does not promote acute arterial thrombosis in mice. J Thromb Haemost: 2014; 12 5 680 689
90. Smalberg J. H., Koehler E., Darwish Murad S., et al. European Network for Vascular Disorders of the Liver (EN-Vie). Fibrinogen γ' and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis. Thromb Haemost: 2013; 109 3 558 560
91. Jobse A., Pieters M., Nienaber-Rousseau C., Boshuizen H., Hoekstra T., de Maat M. P. The contribution of genetic and environmental factors to changes in total and γ' fibrinogen over 5 years. Thromb Res: 2015; 135 4 703 709
92. Kotzé R. C., Nienaber-Rousseau C., De Lange Z., De Maat M. P., Hoekstra T., Pieters M. Genetic polymorphisms influencing total and γ' fibrinogen levels and fibrin clot properties in Africans. Br J Haematol: 2015; 168 1 102 112
93. Grünbacher G., Weger W., Marx-Neuhold E., et al. The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis. Thromb Res: 2007; 121 1 33 36
94. Uitte de Willige S., Pyle M. E., Vos H. L., et al. Fibrinogen gamma gene 3′-end polymorphisms and risk of venous thromboembolism in the African-American and Caucasian population. Thromb Haemost: 2009; 101 6 1078 1084
95. Bahadori B., Uitz E., Dehchamani D., Pilger E., Renner W. The fibrinogen gamma 10034C>T polymorphism is not associated with Peripheral Arterial Disease. Thromb Res: 2010; 126 4 350 352
96. Mannila M. N., Eriksson P., Lundman P., et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost: 2005; 93 3 570 577
97. Uitte DE Willige S., Doggen C. J., DE Visser M. C., Bertina R. M., Rosendaal F. R. Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost: 2006; 4 2 474 476
98. Lovely R. S., Yang Q., Massaro J. M., et al. Assessment of genetic determinants of the association of γ' fibrinogen in relation to cardiovascular disease. Arterioscler Thromb Vasc Biol: 2011; 31 10 2345 2352
99. Kotzé R. C., Ariëns R. A., de Lange Z., Pieters M. CVD risk factors are related to plasma fibrin clot properties independent of total and or γ' fibrinogen concentration. Thromb Res: 2014; 134 5 963 969
100. Nienaber-Rousseau C., de Lange Z., Pieters M. Homocysteine influences blood clot properties alone and in combination with total fibrinogen but not with fibrinogen γ' in Africans. Blood Coagul Fibrinolysis: 2015; 26 4 389 395
101. Hill M., Dolan G. Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias. Haemophilia: 2008; 14 5 889 897
102. de Moerloose P., Boehlen F., Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost: 2010; 36 1 7 17
103. Bornikova L., Peyvandi F., Allen G., Bernstein J., Manco-Johnson M. J. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost: 2011; 9 9 1687 1704
104. Doolittle R. F., Hong S., Wilcox D. Evolution of the fibrinogen γ' chain: implications for the binding of factor XIII, thrombin and platelets. J Thromb Haemost: 2009; 7 8 1431 1433
105. Kollman J. M., Pandi L., Sawaya M. R., Riley M., Doolittle R. F. Crystal structure of human fibrinogen. Biochemistry: 2009; 12;48(18): 3877 3886